Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

Jeffrey C. Goh,Jose Rodriguez,Marine Gross-Goupil,Ulka N. Vaishampayan,Ronald de Wit,Tuomo Alanko,Satoshi Fukasawa,Ken-ichi Tabata,Susan Feyerabend,Raanan Berger,Haiyan Wu,Jeri Kim,Charles Schloss,Johann S. de Bono,Emmanuel S. Antonarakis

Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.

2020

Jeffrey C. Goh
Jose Rodriguez
Marine Gross-Goupil
Ulka N. Vaishampayan
Ronald de Wit
Tuomo Alanko
Satoshi Fukasawa
Ken-ichi Tabata
Susan Feyerabend
Raanan Berger
Haiyan Wu
Jeri Kim
Charles Schloss
Johann S. de Bono
Emmanuel S. Antonarakis

e17584Background: Pembrolizumab monotherapy has shown antitumor activity and acceptable safety in patients with mCRPC previously treated with a next-generation hormone agent (NHA) and docetaxel. Pr...

Keywords:

Oncology
Phases of clinical research
castration resistant
Pembrolizumab
Internal medicine
Prostate cancer
Pathology
Medicine
Docetaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations